Cadrenal Therapeutics, Inc. Common Stock (CVKD) vs Mustang Bio, Inc. (MBIO)
A side-by-side comparison of Cadrenal Therapeutics, Inc. Common Stock and Mustang Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$0.91HealthcareDelayed quote: Oct 6, 2026, 12:11 PM EDT
MBIO
Mustang Bio, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 12:08 PM EDT
Total return — CVKD vs MBIO
growth of $100 · dividends reinvested · last 4yCVKD -98.5% (-64.8%/yr)MBIO -99.9% (-82.8%/yr)CVKD compounded faster over this window
Log scale — wide-divergence pair
CVKD MBIO
CVKD vs MBIO: by the numbers
- •MBIO is the larger company ($3M vs $3M market cap).
Metrics side by side
Valuation
| Metric | CVKD | MBIO |
|---|---|---|
| P/B ratio | 0.80 | 0.46 |
Profitability
| Metric | CVKD | MBIO |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -282.13% | -40.20% |
| ROIC | -284.81% | -45.77% |
Growth (annualized)
| Metric | CVKD | MBIO |
|---|---|---|
| Total return CAGR (5Y) | N/A | -80.80% |
Go deeper
Dig into the metrics
Cadrenal Therapeutics, Inc. Common Stock ROEMustang Bio ROECadrenal Therapeutics, Inc. Common Stock operating marginMustang Bio operating marginCadrenal Therapeutics, Inc. Common Stock revenue growthMustang Bio revenue growthCadrenal Therapeutics, Inc. Common Stock free cash flowMustang Bio free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.